Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery, development, and delivery of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. Its transforming growth factor beta (TGFß) superfamily biology, its novel understanding of the molecular mechanisms of growth factor activation enabled us to develop a proprietary platform for development of monoclonal antibodies that locally and selectively target the precursor. The company develops Apitegromab, an inhibitor of the activation of myostatin that is in Phase 3 clinical trial for the treatment of spinal muscular atrophy; and SRK-181, which has completed Phase 1 clinical trials for the treatment of cancers that are resistant to checkpoint inhibitor therapies, such as anti-PD-1 or anti-PD-L1 antibody therapies. It is developing a pipeline of product candidates to deliver novel therapies to treat a range of serious diseases, including neuromuscular disorders, cardiometabolic disorders, cancer, fibrosis, and iron-restricted anemia. Scholar Rock Holding Corporation was founded in 2012 and is headquartered in Cambridge, Massachusetts.

Scholar Rock Holding Corporation

Barclays analyst Etzer Darout maintained a Buy rating on Scholar Rock Holding today and set a price target of $55.00. According to TipRanks, Darout...

Barclays Sticks to Its Buy Rating for Scholar Rock Holding (SRRK)

Scholar Rock Holding ( ($SRRK) ) just unveiled an announcement. At its June 4, 2026 annual meeting, Scholar Rock shareholders elected four Class II...

	A	B	C	D
1	Symbol	Price	Change	Volume
2	SRRK	$51.27	+4.23%	2.23M
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	SRRK	$51.27	+4.2%	2.23M
3
4
5
6

SRRK

SRRK

No Data Available

Get Scholar Rock Holding Corporation Data in Excel

Get Scholar Rock Holding Corporation Data in Excel